Analyst Gianluca Tucci of Haywood maintained a Buy rating on HEALWELL AI, with a price target of C$4.50.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gianluca Tucci has given his Buy rating due to a combination of factors that highlight HEALWELL AI’s strong financial performance and strategic transformation. The company reported a robust third-quarter performance, surpassing both Haywood’s and consensus estimates in revenue and adjusted EBITDA. The revenue was primarily driven by the SaaS and AI/Data Science segments, with a significant portion being recurring, indicating a stable income stream.
Furthermore, HEALWELL AI’s strategic divestments have streamlined its operations, focusing entirely on the high-growth, high-margin AI and SaaS sectors. The sale of non-core assets, such as its clinical assets and Mutuo Health, has simplified the business model and enhanced its financial flexibility. With a solid cash position bolstered by these divestments, the company is well-positioned to fund future growth initiatives without immediate reliance on external capital.
According to TipRanks, Tucci is ranked #1404 out of 10072 analysts.
In another report released on November 7, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a C$3.80 price target.